BioCompute founder Anagha Rajesh shuts Bengaluru operation and moves to US, explains why: ‘India is not ready’

The founder of health-tech startup BioCompute, Anagha Rajesh, has stirred discussion across India's startup ecosystem after announcing the closure of the company's Bengaluru operations and its relocation to the United States.

In a strongly worded statement explaining the move, Rajesh argued that while India has made significant strides in technology and entrepreneurship, the country remains ill-equipped to support deep-tech healthcare ventures seeking to scale globally.

Her comments have reignited a long-running debate over whether India's startup ecosystem provides sufficient support for cutting-edge scientific innovation, particularly in sectors such as biotechnology, healthcare and artificial intelligence.

‘India is not ready’

Rajesh said the decision was driven by structural challenges rather than a lack of talent.

According to her, India possesses a large pool of skilled engineers, researchers and entrepreneurs, but startups operating at the intersection of healthcare and advanced technology often face obstacles related to funding, regulation and commercial adoption.

She argued that the ecosystem remains heavily focused on consumer technology and software services, while deep-tech and research-intensive ventures continue to struggle for sustained support.

The entrepreneur's remarks quickly gained attention online, with many founders and investors weighing in on the broader issues she raised.

Why the US?

Rajesh cited easier access to specialized investors, stronger research partnerships and a more mature healthcare innovation ecosystem as key reasons behind BioCompute's move.

The United States remains home to many of the world's leading biotechnology companies, research institutions and healthcare-focused venture capital firms. For startups developing advanced medical technologies, proximity to these networks can play a crucial role in accelerating growth.

Industry experts note that many healthcare startups choose to establish operations in the US to gain access to larger markets, regulatory expertise and collaboration opportunities with academic institutions.

Debate within the startup community

The announcement triggered mixed reactions from entrepreneurs and investors.

Some agreed with Rajesh's assessment, arguing that India still faces gaps in research funding, commercialization pathways and long-term support for scientific innovation.

Others pushed back, highlighting the rapid growth of India's startup ecosystem and pointing to successful examples of domestic deep-tech and biotechnology ventures.

Several founders argued that while challenges exist, conditions for innovation have improved significantly over the past decade and continue to evolve.

Broader concerns about deep-tech innovation

The episode has once again highlighted concerns about the difficulties faced by startups operating in highly specialized sectors.

Unlike consumer internet businesses, deep-tech ventures often require years of research, significant capital investment and extensive regulatory approvals before generating revenue.

Supporters of Rajesh's position argue that these realities demand a different funding and policy approach than what currently exists in many emerging startup ecosystems.

What lies ahead for BioCompute?

With its operations now shifting to the United States, BioCompute is expected to focus on expanding its healthcare technology platform and pursuing partnerships within the American medical and research landscape.

For Rajesh, the move represents an effort to place the company in an environment she believes is better suited to its long-term ambitions.

Whether her comments become a catalyst for policy discussions or simply fuel another round of debate within India's startup community, they have undoubtedly reignited questions about what it takes to build globally competitive deep-tech companies from India.